首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備 DDS

市場調查報告書

商品編碼

1623459

全球鼻腔給藥技術市場規模（按產品類型、容器、應用、最終用戶、區域範圍和預測）

Global Nasal Drug Delivery Technology Market Size By Product Type, By Container, By Application, By End- Users, And By Geographic Scope And Forecast

出版日期: 2024年09月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

鼻腔給藥技術市場規模及預測

鼻腔給藥技術市場規模在 2023 年估計為 769.2 億美元，預計到 2031 年將達到 1245.4 億美元，2024 年至 2031 年的複合年增長率為 6.85%。鼻腔給藥技術是透過鼻腔給藥，使藥物直接進入體循環。此技術的優點包括患者依從性好、可透過嗅覺神經將藥物直接輸送到大腦、方便且能達到血液中的治療藥物水平。

預計未來幾年，自我給藥的日益普及和慢性病的增加將推動鼻腔給藥市場的發展。

預計市場將受益於對替代藥物輸送方式、技術進步、新產品創新和併購活動的日益增長的偏好，這些預計將在預測期內推動市場成長。

鼻腔給藥技術的全球市場動態

主要市場驅動因子

慢性呼吸道疾病發生率不斷上升：

全球氣喘、慢性阻塞性肺病（COPD）和過敏性鼻炎等疾病的發生率不斷上升，對以非侵入性、便捷的方式將藥物直接輸送到呼吸道的需求正在迅速增加。更快的吸收速度和提高患者依從性的需求推動了鼻腔給藥解決方案的使用。

自我治療需求不斷成長：

越來越多的患者為了方便和控制治療而尋求自我用藥的選擇。因此，鼻腔給藥系統通常易於使用且只需要極少的培訓，適合在家中自行使用。

藥物配方與輸送技術的進步：

技術的進步促進了新型鼻腔給藥系統的開發，該系統具有更好的標靶給藥、控制釋放和增加生物利用度（進入血液的藥物百分比）。這些進步正在帶來更有效、以患者為中心的治療選擇。

更重視病患的便利性與依從性：

醫療保健產業越來越注重提高病患的便利性和對治療方案的依從性。在這方面，鼻腔給藥具有多種優勢，包括非侵入性、易於使用和快速起效。

主要問題

克服解剖學和生理學障礙：

藥物的有效傳遞和分佈受到鼻腔複雜解剖結構的影響，包括狹窄的空間、黏液清除機制和有限的吸收表面積。

確保藥物傳遞的穩定性：

酵素和黏液的存在通常有助於藥物在鼻腔中的分解。為了應對這些課題，需要仔細考慮藥物輸送到鼻腔的穩定性和控制釋放機制。

病人接受度與易用性：

鼻腔噴霧劑和其他給藥裝置的易用性至關重要，尤其是對於兒科和老年患者而言。解決不適、劑量準確性和鼻腔刺激等潛在副作用等問題對於患者接受度至關重要。

法規要求和嚴格測試：

鼻腔給藥系統受到監管機構制定的嚴格指導方針的約束，包括安全性、有效性和品質控制。合規性要求進行大量的臨床前和臨床測試，這既費時又昂貴。

主要趨勢

越來越多的病患選擇非侵入式、便利的藥物傳遞方式：

非侵入性、便利的藥物傳遞方法越來越受到病患的需求。鼻腔給藥比口服和注射藥物等傳統方法有幾個優點。鼻腔噴霧劑和滴劑通常比藥片或註射劑更容易使用，尤其是對於兒童和老年人。此外，與口服藥物相比，鼻腔給藥的藥物可以到達血液並更快地發揮作用。

自我管理的盛行：

自我用藥的趨勢推動了對使用者友善且方便的鼻腔給藥裝置的需求。這種趨勢對於過敏或偏頭痛等慢性病尤其重要，因為患者需要頻繁服藥。遠距醫療和遠距病人監測的進步為聯網鼻腔給藥裝置的使用創造了機會。這些設備可以監測藥物使用並向醫療保健提供者提供即時數據，增強患者護理管理。

居家醫療保健設備需求不斷成長：

慢性病發病率的上升和向家庭醫療保健的日益轉變推動了對家庭鼻腔給藥設備的需求。這些設備使患者能夠在家中接受治療，從而改善生活品質並降低醫療成本。

Nasal Drug Delivery Technology Market size is estimated at USD 76.92 Billion in 2023 and is projected to reach USD 124.54 Billion by 2031 , growing at a CAGR of 6.85% from 2024 to 2031. Nasal drug delivery technology is a technique utilized for administering drugs through the nasal route, facilitating direct access to systemic circulation. Advantages offered by this technique include good patient compliance, the potential for direct drug delivery to the brain via the olfactory nerves, convenience, and rapid attainment of therapeutic drug levels in the blood.

The Nasal Drug Delivery Technology Market is expected to be driven by the growing adoption of self-administration and increasing incidences of chronic diseases over the predicted years.

The market is anticipated to benefit from the rising preference for an alternative mode of drug administration, technological advancements, new product innovations, and merger & acquisition activities, which are predicted to fuel market growth during the forecasted period.

Global Nasal Drug Delivery Technology Market Dynamics

The key market dynamics that are shaping the Nasal Drug Delivery Technology Market include:

Key Market Drivers

Rising Prevalence of Chronic Respiratory Diseases:

The growing prevalence of conditions like asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis worldwide is surging demand for a non-invasive and convenient way to administer medication directly to the respiratory tract. This need for faster absorption and improved patient compliance is spurring the use of nasal drug delivery solutions.

Growing Demand for Self-Administered Treatments:

Self-administered medication options are increasingly sought by patients for enhanced convenience and control over their treatment. Thus, nasal drug delivery systems are often user-friendly and require minimal training, making them suitable for self-administration at home.

Technological Advancements in Drug Formulation and Delivery:

Advancements in technology are facilitating the development of novel nasal drug delivery systems with improved targeted delivery, controlled release, and enhanced bioavailability (the proportion of a drug that enters the bloodstream). These advancements are leading to the creation of more effective and patient-centric treatment options.

Increasing Focus on Patient Convenience and Compliance:

The healthcare industry is witnessing a growing emphasis on improving patient convenience and compliance with treatment regimens. Nasal drug delivery offers several advantages in this regard, including its non-invasive nature, ease of use, and rapid onset of action.

Key Challenges

Overcoming Anatomical and Physiological Barriers:

The efficient delivery and distribution of drugs is affected by the complex structure of the nasal cavity, which includes narrow spaces, mucus clearance mechanisms, and limited absorption surface area.

Ensuring Drug Stability and Delivery:

Drug degradation in the nasal cavity is often facilitated by enzymes and the presence of mucus. Formulating drugs for nasal delivery requires careful consideration of stability and controlled release mechanisms to address these challenges.

Patient Acceptance and Usability:

User-friendliness of nasal sprays and other delivery devices is particularly crucial, especially for children or elderly patients. Addressing issues such as discomfort, dosing accuracy, and potential side effects like nasal irritation is essential for patient acceptance.

Regulatory Requirements and Stringent Testing:

Strict guidelines for nasal drug delivery systems, encompassing safety, efficacy, and quality control, are imposed by regulatory agencies. Compliance necessitates extensive preclinical and clinical testing, which can be both time-consuming and expensive.

Key Trends

Rising Patient Preference for Non-Invasive and Convenient Drug Delivery:

Non-invasive and convenient drug delivery methods are increasingly sought by patients. Several advantages are offered by nasal drug delivery over traditional methods such as oral or injectable medications. These advantages include: nasal sprays and drops are generally found to be easier to use than pills or injections, particularly for children or elderly patients, drugs administered nasally can reach the bloodstream and take effect more quickly compared to orally administered medications, and nasal delivery bypasses the digestive system, potentially minimizing side effects like nausea or stomach upset.

Growing Adoption of Self-Administration Practices:

The trend toward self-administration of medications is propelling the demand for user-friendly and convenient nasal drug delivery devices. This trend is particularly relevant for chronic conditions such as allergies or migraines, where patients may require frequent medication administration. Opportunities are emerging for the use of connected nasal drug delivery devices due to advancements in telemedicine and remote patient monitoring. These devices can monitor medication usage and furnish real-time data to healthcare providers, enhancing patient care management.

Increasing Demand for Home Healthcare Devices:

The rising prevalence of chronic diseases and the growing shift towards home healthcare are fueling the demand for home-based nasal drug delivery devices. These devices enable patients to receive treatment in their own homes, thereby enhancing their quality of life and reducing healthcare costs.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Nasal Drug Delivery Technology Market Regional Analysis

Here is a more detailed regional analysis of the Nasal Drug Delivery Technology Market:

North America

Novel nasal drug delivery technologies are heavily invested in by North American institutions, leading to market domination.

Approval of new technologies is expedited by favorable regulatory frameworks, such as the FDA's, solidifying North America's dominance.

Nasal drug delivery methods are widely accepted by the public, creating a strong North American market for new products.

Innovation and market growth in the nasal drug delivery sector are fueled by a thriving venture capital ecosystem, further strengthening North America's leading position.

Asia Pacific

Increasing investment in research and development by Asian Pacific institutions drives advancements in nasal drug delivery technology.

Regulatory reforms and streamlined approval processes in the region encourage the adoption of novel nasal drug delivery technologies.

Growing awareness and acceptance of nasal drug delivery methods among the population in the Asia Pacific contribute toward helping it grow at a rapid rate over the forecast period.

Global Nasal Drug Delivery Technology Market: Segmentation Analysis

The Global Nasal Drug Delivery Technology Market is Segmented on the basis of Product Type, Container, Application, End-Users, and Geography.

Nasal Drug Delivery Technology Market, By Product Type

Sprays
Drops
Gels
Powders
Inhalers

Based on Product Type, the market is segmented into Sprays, Drops, Gels, Powders, and Inhalers. The highest market share in the Nasal Drug Delivery Technology Market is held by nasal sprays. Nasal sprays are favored due to their ease of administration, rapid onset of action, and suitability for delivering a wide range of medications, making them the preferred choice for both patients and healthcare providers. Their dominant position in the market is significantly contributed to by their versatility and effectiveness.

Nasal Drug Delivery Technology Market, By Application

Allergic Rhinitis
Congestion
Infections
Vaccination
Opioid Overdose Reversal
Others

Based on Application, the market is segmented into Allergic Rhinitis, Congestion, Infections, Vaccination, Opioid Overdose Reversal, and Others. The Nasal Drug Delivery Technology Market is dominated by Allergic Rhinitis. It is prevalent worldwide and drives the demand for nasal drug delivery systems due to the frequent need for medication administration. Nasal sprays are commonly utilized to alleviate allergic rhinitis symptoms because of their rapid onset of action and targeted delivery to the nasal mucosa.

Nasal Drug Delivery Technology Market, By End-Users

Hospitals
Clinics
Ambulatory Surgical Centers
Homecare Settings
Others

Based on End-Users, the market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings, and Others. Homecare Settings dominate the Nasal Drug Delivery Technology Market. This dominance is attributed to the rising trend of self-administration and the convenience of using nasal drug delivery systems at home. Advancements in technology have enabled the development of user-friendly devices suitable for home use, further driving the demand in this segment.

Nasal Drug Delivery Technology Market, By Container

Non-Pressurized
Pressurized

Based on Container, the market is segmented into Non-Pressurized and Pressurized containers. Non-pressurized segment is anticipated to dominate the market over the forecast period. Growing concerns about environmental impact and potential health risks associated with propellants is surging demand for alternative delivery methods such as pumps or atomizer mechanisms.

Key Players

The "Nasal Drug Delivery Technology Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., AstraZeneca PLC, AptarGroup Inc., Aegis Therapeutics LLC, 3M, Becton, Dickinson, and Company.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, along with product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

Nasal Drug Delivery Technology Market Recent Developments
In October 2023, the launch of its Unidose+ nasal spray platform was announced by Aptar Pharma, a leading provider of drug delivery systems, specifically designed for high-viscosity and challenging-to-formulate drugs.
In September 2023, a collaboration agreement was entered into by Vectura Group, a pharmaceutical company specializing in inhalation and nasal drug delivery, with ALX Oncology to develop and commercialize a novel nasal spray formulation of ALX148 for the treatment of head and neck cancers.
In August 2023, the approval of AstraZeneca's RINVOQ nasal spray by the U.S. Food and Drug Administration (FDA) was announced, making it the first IL-12/23 inhibitor approved for the treatment of moderate-to-severe chronic rhinosinusitis with nasal polyps.

1 INTRODUCTION OF GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY CONTAINER

5.1 Overview
5.2 Non-Pressurized
5.3 Pressurized

6 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCT TYPE

6.1 Overview
6.2 Sprays
6.3 Drops
6.4 Gels
6.5 Powders
6.6 Inhalers

7 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY END-USERS

7.1 Overview
7.2 Hospitals
7.3 Clinics
7.4 Ambulatory Surgical Centers
7.5 Homecare Settings
7.6 Others

8 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY THERAPEUTIC APPLICATION

8.1 Overview
8.2 Allergic Rhinitis
8.3 Congestion
8.4 Infections
8.5 Vaccination
8.6 Opioid Overdose Reversal
8.7 Others

9 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES

11.1 Merck & Co., Inc.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Novartis AG
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Glaxosmithkline PLC
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Johnson & Johnson Services, Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Pfizer Inc.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Astrazeneca PLC
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Aptargroup, Inc.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Aegis Therapeutics LLC
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 3M
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Becton Dickinson and Company
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments